Log in to your Inderes Free account to see all free content on this page.
Toleranzia
0.584
SEK
-1.02 %
TOL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
-1.02%
+2.46%
+19.43%
-8.75%
+36.45%
+21.67%
-50.09%
-79.83%
-91.14%
Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.
Read moreMarket cap
158.24M SEK
Turnover
63.85K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
21.2.
2025
Annual report '24
ShowingAll content types
Toleranzia AB publishes the Nomination Committee
Toleranzia receives approximately SEK 37 million through the warrants of series TO4 which were exercised to approximately 85 percent
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio